|
Besides the line of specialty generics, IMPAX is developing a line of proprietary drugs with a focus on the treatment of Central Nervous System (CNS) disorders. These disorders include ailments such as Alzheimer’s disease, attention deficit hyperactivity, depression, epilepsy, migraines, multiple sclerosis, Parkinson’s disease, and schizophrenia.
According to IMS Health Incorporated data, CNS is the largest therapeutic category in the US with 2002 retail sales of $32 billion, or 15.7% of the $203 billion US retail drug market. CNS drug sales grew 10.4% in 2002 versus a sales growth of 9.1% for the entire industry.
The executive management team of IMPAX has extensive experience developing and marketing CNS products. Our strategy is to build this portfolio primarily through internal development and, in addition, through licensing and acquisition. We intend to utilize our formulation and development expertise as well as our drug delivery technologies in the formulation of off-patent drug substances as differentiated, modified, or controlled-release pharmaceutical products that we will market as brand name products.
| 
